رجوع
39
59
مُدرج أيضًا باسم
SNN
NYSE
نطاق اليوم
KWD 16.05
KWD 16.50
نطاق 52 أسبوعًا
KWD 12.55
KWD 18.50
حجم التداول
2,700
متوسط 50 يوم / 200 يوم
KWD 17.02
/
KWD 16.45
الإغلاق السابق
KWD 16.05
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Healthcare (627 نظير)
| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | 21.9 | 0.4 |
| P/B | 2.6 | 2.9 |
| ROE % | 12.1 | 3.9 |
| Net Margin % | 10.1 | 3.8 |
| Rev Growth 5Y % | 4.9 | 10.0 |
| D/E | 0.6 | 0.2 |
النقاط الرئيسية
Revenue grew 4.86% annually over 5 years — modest growth
Earnings grew 55.07% over the past year
ROE of 12.10% — decent returns on equity
Generating 870.95M in free cash flow
PEG of 0.39 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3.59%
النمو
Revenue Growth (5Y)
4.86%
Revenue (1Y)8.45%
Earnings (1Y)55.07%
FCF Growth (3Y)119.36%
الجودة
Return on Equity
12.10%
ROIC8.91%
Net Margin10.14%
Op. Margin16.27%
الأمان
Debt / Equity
0.63
Current Ratio2.57
Interest Coverage6.43
التقييم
P/E Ratio
21.93
P/B Ratio2.64
EV/EBITDA16.37
Dividend Yield0.02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 8.45% | Revenue Growth (3Y) | 6.56% |
| Earnings Growth (1Y) | 55.07% | Earnings Growth (3Y) | 55.86% |
| Revenue Growth (5Y) | 4.86% | Earnings Growth (5Y) | 5.08% |
| Profitability | |||
| Revenue (TTM) | 6.30B | Net Income (TTM) | 638.90M |
| ROE | 12.10% | ROA | 6.10% |
| Gross Margin | 68.01% | Operating Margin | 16.27% |
| Net Margin | 10.14% | Free Cash Flow (TTM) | 870.95M |
| ROIC | 8.91% | FCF Growth (3Y) | 119.36% |
| Safety | |||
| Debt / Equity | 0.63 | Current Ratio | 2.57 |
| Interest Coverage | 6.43 | Dividend Yield | 0.02% |
| Valuation | |||
| P/E Ratio | 21.93 | P/B Ratio | 2.64 |
| P/S Ratio | 2.22 | PEG Ratio | 0.39 |
| EV/EBITDA | 16.37 | Dividend Yield | 0.02% |
| Market Cap | 14.01B | Enterprise Value | 16.78B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.30B | 5.81B | 5.55B | 5.22B | 5.21B |
| Net Income | 638.90M | 412.00M | 263.00M | 223.00M | 524.00M |
| EPS (Diluted) | 0.73 | 0.47 | 0.30 | 0.26 | 0.59 |
| Gross Profit | 4.29B | 4.05B | 3.82B | 3.68B | 3.67B |
| Operating Income | 1.03B | 657.00M | 425.00M | 450.00M | 593.00M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 10.47B | 10.35B | 9.99B | 9.97B | 10.92B |
| Total Liabilities | 5.18B | 5.09B | 4.77B | 4.71B | 5.35B |
| Shareholders' Equity | 5.30B | 5.27B | 5.22B | 5.26B | 5.57B |
| Total Debt | 3.33B | 3.32B | 3.08B | 2.87B | 3.34B |
| Cash & Equivalents | 557.89M | 619.00M | 302.00M | 350.00M | 1.29B |
| Current Assets | 4.11B | 4.42B | 4.03B | 3.86B | 4.42B |
| Current Liabilities | 1.60B | 1.53B | 2.27B | 1.72B | 2.13B |
درجات الاستراتيجيات
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#631 of 1052
Growth + Value
Growth at a Reasonable Price (Peter Lynch)
#107 of 332
النشاط الأخير
دخل
Cash Flow Compounder
Mar 24, 2026
دخل
Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026